Innovation & TechCognizant to apply generative AI to enhance drug discovery

Cognizant to apply generative AI to enhance drug discovery

Must Read

Teaneck – April 2024- Cognizant leverages the NVIDIA BioNeMo platform to advance generative AI (gen AI) technology, addressing complex drug discovery challenges in the life sciences industry. This includes enhancing productivity in the development process and accelerating the speed of bringing new, life-saving treatments to market.

Traditional drug discovery methodologies are process intensive and require the analysis of vast repositories of scientific literature and clinical data to reveal relevant insights. Furthermore, high costs burden traditional methods, along with long development lifecycles and a high rate of failure. By leveraging gen AI technologies, clinical researchers can rapidly sift through extensive datasets, more accurately predict interactions between drug compounds and create new, viable drug development pathways.

“More than any other technological breakthrough in recent decades, generative AI has the potential to revolutionize the way new drugs are researched, developed and brought to market, making the creation of lifesaving discoveries faster, smarter and more accessible to all,” said Anna Elango, EVP, Cognizant’s Core Technologies & Insights. “By collaborating with NVIDIA, Cognizant can open the path to realizing this vision safely, responsibly and cost-effectively for our life sciences clients.”

By leveraging its deep life sciences and AI domain expertise and NVIDIA’s pretrained, industry-specific generative AI models offered as part of BioNeMo, Cognizant aims to give clients access to a suite of model-making services, including pretrained models, cutting-edge frameworks, and APIs, that offers clients the quickest path to train and customize enterprise models using their proprietary data. This offering aims to enable this with reduced manual intervention for data analysis, eliminating the need to write elaborate code or build/maintain infrastructure.

“Generative AI will drive the next wave of enterprise productivity gains across industries, enabled by the NVIDIA AI Enterprise software platform,” said Alvin DaCosta, VP, Global Consulting Partner Organization, NVIDIA. “Using NVIDIA BioNeMo, Cognizant will help provide its life sciences clients with advanced, secure and reliable AI services to drive improved outcomes with custom drug discovery applications.”

Also Read: The AI-powered Future: Will We Live Healthier, Longer Lives?

Cognizant collaborates with leading global firms in pharmaceuticals, biotech and medical devices, covering the entire life sciences value chain from R&D to digital health. This work contributes to the industry’s ability to enhance science, improve patient outcomes, and increase business value, by enabling a patient-centric approach and better interactions with healthcare professionals. Cognizant’s life sciences offerings support more than 120 global manufacturing lines and more than 18 million patients with medical device company products.

Cognizant intends to pursue additional applications by collaborating with NVIDIA in areas such as manufacturing and automotive engineering, where gen AI has the potential to enhance productivity, optimize costs and bring innovation to market more quickly. Cognizant intends to establish an NVIDIA AI Center of Excellence this year to further innovate with NVIDIA technologies, including the NVIDIA Metropolis, NVIDIA Omniverse and NVIDIA AI Enterprise platforms, for the benefit of clients across industries around the world.

- Advertisement -

Recent

World Hypertension Day: Five Natural Ways to Lower Blood Pressure

One in three adults worldwide has high blood pressure according to the World Health Organization(WHO). Left untreated, the condition...
- Advertisement -